PI3K-delta syndrome; PASLI disease

From Aaushi
Jump to navigation Jump to search

Pathology

Clinical manifestations

Management

More general terms

References

  1. Rao VK et al A randomized, placebo-controlled phase 3 trial of the PI3Kdelta inhibitor leniolisib for activated PI3Kdelta syndrome Blood. 2023 Mar 2;141(9):971-983 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36399712 PMCID: PMC10163280 Free PMC article